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Introduction
Synucleinopathies are a heterogenous group of  neurodegenerative diseases characterized by the formation 
of  α-synuclein (α-syn) aggregates. Parkinson’s disease (PD) is the second most common neurodegenerative 
disorder after Alzheimer’s disease and is characterized by motor and nonmotor symptoms. The motor 
symptomatology is mainly associated with profound dopamine depletion in the striatum due to the loss of  
mesencephalic dopaminergic neurons. The main neuropathological hallmark of  PD is the presence of  neu-
ronal α-syn–positive intracytoplasmic inclusions named Lewy bodies (LB) in cell bodies and Lewy neurites 
in cell processes (1). Multiple system atrophy (MSA) is a rare, fast-progressing disease divided in 2 clinical 
phenotypes: (a) the MSA parkinsonian showing L-3,4-dihydroxyphenylalanine nonresponsive parkinso-
nian syndrome with bradykinesia, rigidity, and rest tremor due to a dopaminergic loss in the nigrostriatal 
pathway; and (b) the MSA cerebellar exhibiting cerebellar syndrome with gait, speech, and limb ataxia, 
and cerebellar oculomotor dysfunction caused by a neuronal loss in the olivopontocerebellar pathway. The 
neuropathological hallmark of  MSA is the presence of  α-syn–positive cytoplasmic inclusions, in oligoden-
drocytes, named glial cytoplasmic inclusions (2).
The presence of  α-syn–positive aggregates suggests that a defect in α-syn degradation could play a role in 
the accumulation of  the aggregated and misfolded proteins in these neurodegenerative disorders (3, 4). α-Syn 
degradation is ensured by the 2 protein degradation pathways: the ubiquitin-proteasome system (5) and the 
autophagy-lysosomal pathways (ALP) through both macroautophagy and chaperone-mediated autophagy 
(6–9). The ALP is a versatile cellular proteolytic system allowing the degradation of  long-lived protein, pro-
tein aggregates, and abnormal organelles — among other cellular waste — through different mechanisms (10). 
The synucleinopathies Parkinson’s disease (PD) and Multiple system atrophy (MSA) — 
characterized by α-synuclein intracytoplasmic inclusions into, respectively, neurons and 
oligodendrocytes — are associated with impairment of the autophagy-lysosomal pathways (ALP). 
Increased expression of the master regulator of ALP, transcription factor EB (TFEB), is hypothesized 
to promote the clearance of WT α-synuclein and survival of dopaminergic neurons. Here, we 
explore the efficacy of targeted TFEB overexpression either in neurons or oligodendrocytes to 
reduce the pathological burden of α-synuclein in a PD rat model and a MSA mouse model. While 
TFEB neuronal expression was sufficient to prevent neurodegeneration in the PD model, we 
show that only TFEB oligodendroglial overexpression leads to neuroprotective effects in the MSA 
model. These beneficial effects were associated with a decreased accumulation of α-synuclein into 
oligodendrocytes through recovery of the ALP machinery. Our study demonstrates that the cell type 
where α-synuclein aggregates dictates the target of TFEB overexpression in order to be protective, 
paving the way for adapted therapies.
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Macroautophagy allows degradation after the formation and fusion of  cargo-vesicles called autophagosomes 
carrying the material with lysosomes containing enzymatic material (10). Chaperone-mediated autophagy is 
a selective pathway allowing the degradation of  protein after recognition of  pentapeptide (KFERQ-like motif) 
by the cytosolic chaperone heat-shock cognate 70 kDa protein and delivery to the lysosome. Genetic and 
neuropathological evidence suggest that ALP defects are involved in the pathogenesis of  neurodegenerative 
disorders. Relevant to synucleinopathies, several lines of  evidence suggest that the assembly state of  α-syn can 
affect the degradation machinery. In particular, monomeric and small soluble oligomeric forms of  α-syn are 
degraded through the ubiquitin-proteasome system or chaperone-mediated autophagy, whereas larger oligo-
meric or aggregated forms are cleared by macroautophagy (11, 12).
Similar to PD, impairment of  the ALP occurs in MSA. Postmortem studies showed that the micro-
tubule-associated protein 1 light chain 3β (LC3B) autophagosome marker is increased and present within 
glial cytoplasmic inclusions in brains of  MSA patients (13–15). Recently, it has also been demonstrated that 
the ALP is impaired in induced pluripotent stem cells–derived dopaminergic neurons from MSA patients, 
with decreased autophagic flux leading to further accumulation of  nondegraded autophagosomes (16). 
Thus, defects in the ALP might be involved in the accumulation of  α-syn in oligodendrocytes contributing 
to neurodegeneration in MSA. Enhancing ALP, thus, appears as a putative attractive approach for prevent-
ing accumulation of  α-syn in synucleinopathies (10).
Transcription factor EB (TFEB) has emerged as a master activator of  the autophagy machinery, as 
it regulates the expression of  lysosomal genes through the Coordinated Lysosomal Expression and Reg-
ulation (CLEAR) signaling network, enhancing both lysosomal biogenesis and autophagy (17–22). In the 
context of  PD, overexpression of  TFEB has been shown to attenuate dopaminergic cell death and motor 
deficits induced by adeno-associated virus–mediated (AAV-mediated) overexpression of  WT α-syn in rats 
through autophagy enhancement (23). Moreover, the important role of  TFEB in the lysosomal-associated 
α-syn clearance has been elucidated in a genetic and chemical activation model of  TFEB in vitro (24, 25). 
Recently, it has been also reported that overexpression of  TFEB in 1-methyl-4-phenyl-1,2,3,6-tetrahydropy-
ridine–intoxicated (MPTP-intoxicated) mice induces neurotrophic effects — in addition to its neuroprotec-
tive effects on dopaminergic neurons (26). Here, we investigate whether cell-specific induction of  the ALP 
through AAV-mediated TFEB overexpression may exert beneficial effects in a viral-based rat model of  PD 
and in the transgenic PLP α-syn mouse model of  MSA by targeting cellular-specific overexpression of  TFEB.
Results
TFEB overexpression induces neuroprotection in the A53T–α-Syn rat model of  PD. Since TFEB overexpression 
has been shown to be neuroprotective against AAV-mediated WT α-syn overexpression in rats (23), we first 
aimed at extending this observation through the assessment of  the effects of  increasing the ALP through 
TFEB overexpression in a rat model of  PD based, this time, on the overexpression of  human mutated 
A53T–α-syn. We used 2 AAV pseudotype 2/9 to deliver either human A53T–α-syn under the human 
synapsin-1 promoter with the cytomegalovirus (CMV) enhancer (CMVie/hSyn; AAV2/9-CMVie/hSyn-
A53T–α-Syn) or 3×Flag-tagged murine TFEB (AAV2/9-CMV-mTFEB-3×Flag) under the CMV promoter. 
Both viruses were coinjected unilaterally in the substantia nigra pars compacta (SNpc). Four months after 
surgery, we validated that both viruses allowed expression of  their respective transgenes in dopaminergic 
neurons, identified by tyrosine-hydroxylase (TH) immunostaining (Supplemental Figure 1, A–C; supple-
mental material available online with this article; https://doi.org/10.1172/jci.insight.129719DS1).
Four months after stereotactic surgery, we observed that coinjection of  AAV-TFEB and AAV–A53T–α-
syn was able to prevent behavioral impairments induced in this model of  PD (Figure 1, A and B, and ref. 27). 
Indeed, TFEB overexpression maintained the use of  the paw contralateral to the lesion in the cylinder test 
(F[3,26] = 15.71, P < 0.0001) and significantly decreased amphetamine-induced rotation (F[3,24] = 6.733, P = 
0.0019). Immunohistological investigations revealed that the dopaminergic nigrostriatal tract was preserved 
when TFEB was coexpressed with mutated α-syn at both striatal dopaminergic terminals (Figure 1C; F[3,23] = 
21.07, P < 0.0001) and SNpc dopaminergic neurons (Figure 1C; F[3,23] = 12.83, P < 0.0001) levels.
Further investigations showed that TFEB overexpression significantly decreased the pathological 
burden of  α-syn with (a) a reduction of  human mutated α-syn accumulation (Figure 1D; ~50% reduc-
tion; [F(3,8) = 50.6, P < 0.0001]), (b) a dramatic decrease in pathological Serine129 phosphorylated 
α-syn (pS129–α-syn) staining levels in the SNpc (Figure 1E), and (c) a dampening of  the induced 
astrogliosis in the SN (Supplemental Figure 1D). Altogether, these results both confirm and extend the 
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proposal that overexpression of  TFEB might be beneficial in experimental PD and also validate our 
TFEB transgene.
Levels of  TFEB are decreased in MSA patient brains. Impaired TFEB function bas been previously reported 
in neurodegenerative diseases such as Alzheimer’s disease (28) and PD (23), but its potential impairment 
in MSA is still unknown. We thus determined whether defects in TFEB may also occur in MSA patients 
(Supplemental Table 1). Being a transcription factor, we investigated the subcellular localization of  TFEB. 
We measured protein expression levels of  TFEB in nuclear and cytosolic fractions from frontal cortex and 
putamen lysates of  healthy individuals and MSA patients. We observed that TFEB protein levels were 
significantly reduced in the nuclear fractions in the putamen of  MSA patients compared with healthy indi-
viduals (Figure 2, A and B, P = 0.037) and, to a lesser extent, in the frontal cortex (Figure 2, C and D), a 
brain region less affected in MSA parkinsonian cases. These observations suggest a defect in TFEB nuclear 
Figure 1. TFEB overexpression prevents mutant A53T–α-syn toxicity in a rat model of Parkinson’s disease. (A) TFEB overexpression restores the use 
of left paw in the cylinder test. (B) TFEB overexpression alleviates amphetamine-induced rotation behavior (1 mg/kg). (C) TFEB overexpression prevents 
α-syn–induced dopaminergic degeneration. Left lane and upper plot: representative images and quantification of striatal tyrosine hydroxylase (TH) 
staining. Right lane and lower plot: representative images of mesencephalic section of TH staining and stereological counting of TH-positive cells in the 
substantia nigra (SN). Inverted green fire blue lookup table was used to enhance visualization of the lesion. (D) Representative images and surface quanti-
fication of human α-syn staining in the SN. Scale bar: 50 μm. (E) Representative images of Serine129-phosphorylated α-syn in the SN. Scale bar: 500 μm. 
Data represent mean ± SEM. Comparisons were made using 1-way ANOVA and Bonferroni’s correction for multiple comparison, n = 7–8 per group.  
*P < 0.05 vs. sham-injected animals. $P < 0.05 vs. hSynA53T-injected animals. 
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translocation associated with a possible reduction in TFEB transcriptional activity, similar to other neuro-
degenerative diseases.
Sustainable cell-specific expression of  exogenous TFEB in the SN of  PLP mice. To address the therapeutic 
potential of  restoring TFEB levels in a clinically relevant mouse model of  MSA, we aimed at overexpress-
ing TFEB in a transgenic mouse model of  MSA expressing human WT α-syn under the control of  the oli-
godendrocyte-specific promoter PLP (hereafter referred as PLP mice) (29–33). In the PD-relevant exper-
iments, human α-syn was expressed in SNpc neurons. In the MSA-relevant experiments, we compared 
the effects of  neuronal vs. oligodendroglial TFEB overexpression. To this end, we employed the CMVie/
hSyn promoter to drive neuron-specific expression of  HA-tagged mTFEB (CMVie/hSyn-mTFEB-HA) 
and the myelin basic protein (MBP) promoter for oligodendrocyte-specific expression of  3×Flag-tagged 
mTFEB (MBP-mTFEB-3×Flag). To validate and determine the protein expression level of  exogenous 
TFEB, we transiently expressed the 2 constructs in HEK293T cell lines and performed immunoblotting 
against TFEB, HA, and Flag (Figure 3, A and B). Transfected cells exhibited over 2-fold increase for each 
cell type–specific promoter with similar levels of  expression between the 2 promoters (Figure 3, A and B).
AAV2/9-mediated transgene expression was then evaluated in vivo 5 months after intranigral injec-
tion in WT and PLP mice (Figure 3, C–F, and Supplemental Figure 2). Under the CMVie/hSyn promot-
er, TFEB expression was identified in the cytoplasm and the nucleus of  nigral TH-positive dopaminergic 
cells (Figure 3C), confirming neuronal expression. After 5 months, TFEB protein levels were increased 
by 10-fold in comparison with control mice for CMVie/hSyn-mTFEB-HA–injected mice (Figure 3D). 
Likewise, viral vectors expressing TFEB under the MBP promoter showed transgene expression into the 
cytoplasm and the nucleus of  nigral oligodendrocytes (Figure 3E) and 1.5-fold increase in MBP-mTFEB-
3×Flag–injected mice (Figure 3F). We thus were able to drive the overexpression of  TFEB in the SN of  WT 
and PLP mice in a cell-specific manner. The nuclear localization of  exogenous TFEB either in neurons or 
Figure 2. Reduced TFEB protein expression in MSA nuclear fractions in putamen and frontal cortex. (A and B) Representative immunoblot levels of TFEB 
in nuclear and cytosolic fractions from putamen of healthy individuals (n = 6) and MSA patients (n = 7). (C and D) TFEB immunoblot levels in nuclear and 
the cytosolic fractions from frontal cortex of age-matched healthy individuals and MSA patients. The term nuclear TFEB corresponds to the measured 
TFEB protein levels into the nuclear fraction normalized by Lamin protein levels. The term cytosolic TFEB corresponds to the measured TFEB protein levels 
into the cytosolic fraction normalized by Actin protein levels. The ratio of nuclear TFEB divided by cytosolic TFEB is then presented on the graph for each 
region. Data represent mean ± SEM. Comparisons were made using nonparametric t test. *P < 0.05 compared with healthy individuals. 
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in oligodendrocytes demonstrated the long-term expression level in AAV-mTFEB–transduced cells and the 
efficiency of  TFEB to be translocated to the nucleus to exert its transcriptional activity (34, 35).
Oligodendroglial-targeted TFEB overexpression rescues dopaminergic neurodegeneration in PLP mice. Next, 
we hypothesized that cell type–specific expression of  TFEB would differentially protect against neuro-
degeneration in PLP mice. As previously reported (29–33), noninjected control PLP mice displayed an 
approximately 30% loss of  SN dopaminergic cells, as determined by stereological counting of  SN TH- and 
Nissl-positive cells (Figure 4, A and B; F[1,29] = 30.52, P = 0.0017) and a 15% loss of  striatal dopaminergic 
terminals, as assessed by measurement of  the optical density of  TH-positive staining (Figure 4, C and D).
Interestingly, neuronal expression of  TFEB in PLP mice did not afford neuroprotection, as we 
observed similar dopaminergic neurodegeneration both at the level of  SN cell bodies and striatal termi-
nals, compared with control mice (Figure 4, A–D). In contrast, oligodendroglial-targeted expression of  
TFEB attenuated neurodegeneration compared with neuronal-targeted TFEB in PLP mice, both at the 
level of  SN dopaminergic neuron cell bodies and striatal dopaminergic neurons (Figure 4, A–D). Overall, 
these data indicated that only oligodendroglial-targeted TFEB overexpression can prevent nigrostriatal 
neurodegeneration in the PLP mouse model of  MSA.
Overexpression of  TFEB in oligodendrocytes modestly prevents α-syn accumulation in the nigrostriatal pathway 
of  PLP mice. We next determined whether the neuroprotection associated with TFEB expression observed 
in PLP mice was also accompanied by a reduction of  markers of  synucleinopathy (i.e., our hypothesized 
primary target for enhanced ALP). We examined the effects of  TFEB overexpression on α-syn species 
identified by a human-specific α-syn antibody in the absence or presence of  proteinase K (PK) pretreat-
ment (Figure 5A). PK treatment reveals the accumulation of  misfolded PK-resistant α-syn aggregates, as 
reported in this transgenic PLP α-syn mouse model of  MSA (29–33). Without PK treatment, no significant 
differences were observed regarding the number of  α-syn–positive dots per μm² counted by stereology in 
the SN of  injected PLP mice compared with control PLP animals (Figure 5B). Following PK digestion, 
however, AAV-MBP-mTFEB–injected PLP mice exhibited a marked reduction of  PK-resistant aggregates 
in the SN compared with control mice (Figure 5C). However, no significant differences were observed in 
α-syn staining in the striatum in the 3 experimental groups (Figure 5, E and F).
To further characterize the effect of  TFEB regarding α-syn pathology, we performed immunohistochem-
ical investigations in the SN and the striatum with a phospho-specific Serine129 α-syn (pS129–α-syn) anti-
body used as a second indicator of  pathological α-syn (Figure 5, A and E). We observed an increase in the 
number of  pS129 α-syn dots per μm² in the SN of  the CMVie/hSyn-mTFEB PLP mice compared with 
control PLP mice (Figure 5D). No significant differences were observed regarding pS129–α-syn immunos-
taining in the striatum (Figure 5G). Our results indicate that only oligodendroglial-targeted TFEB overex-
pression modestly reduces the burden of  α-syn pathology, through the pathological PK-resistant species of  
α-syn, whereas neuronal-targeted TFEB had no effect or rather enhanced the accumulation of  pS129–α-syn.
Oligodendroglial TFEB–mediated neuroprotection is independent of  astrogliosis and microgliosis in PLP mice. Given 
the importance of the astroglial and microglial reaction in neurodegeneration, we next assessed the extent of  
astrogliosis and microgliosis using glial fibrillary acidic protein (GFAP) and ionized calcium-binding adapt-
er molecule 1 (Iba1) immunostaining, respectively. No significant differences were observed between the 3 
experimental groups regarding GFAP immunoreactivity in the SN (Figure 6, A and B). At the striatal level, we 
obtained a significant astrogliosis between PLP and WT mice, which was reduced in the CMVie/hSyn-mTFEB 
Figure 3. Sustainable TFEB transgene expression in vitro and in vivo. (A) Representative images (top) and quantification (bottom) of TFEB and HA tag 
immunoblotting in HEK293T cells transfected for 48 hours with the mTFEB-expressed plasmid under the neuronal CMVie/Synapsin promoter (CMVie/Syn-
apsin-mTFEB-HA-WPRE). (B) Representative images (top) and quantification (bottom) of TFEB and Flag tag immunoblotting in HEK293T cells transfected 
for 48 hours with the mTFEB-expressed plasmid under the oligodendroglial promoter MBP (MBP-mTFEB-3×Flag-WPRE). Data represent mean ± SEM. Com-
parisons were made using nonparametric t test. *P < 0.05 compared with nontransfected cells. (C) Confocal images using HA tag and tyrosine hydroxylase 
(TH) antibodies in the ipsilateral SN of mice injected with the CMVie/Synpasin-mTFEB-HA virus 5 months after the injection. The white arrows indicate the 
presence of HA-tagged mTFEB signal into the nucleus of TH-positive neurons. Scale bar: 10 μm. (D) Representative images (top) and quantification (bottom) 
of HA tag immunoblotting in the ipsilateral SN of CMVie/Synapsin-mTFEB-HA–injected WT and PLP mice 5 months after the injection. n = 5 per group. Data 
represent mean ± SEM. Comparisons were made using 1-way ANOVA and Tukey’s correction for multiple comparisons. White bars, control; blue bars, CMVie/
Synapsin-mTFEB-HA. (E) Confocal images using Flag tag and CNPase antibodies in the ipsilateral SN of mice injected with the MBP-mTFEB-3×Flag virus 
5 months after the injection. The white arrow indicates the presence of Flag tag signals into the nucleus of CNPase-positive oligodendrocytes. Scale bar: 
10 μm. (F) Representative images (top) and quantification (bottom) of Flag tag immunoblotting in the ipsilateral SN of MBP-mTFEB–injected WT and PLP 
mice 5 months after the injection. Data represent mean ± SEM. Comparisons were made using 1-way ANOVA and Tukey’s correction for multiple compari-
sons. White bars, control; green bars, MBP-mTFEB-3×Flag. In A, B, D, and F, lanes were run on the same gel but were noncontiguous.
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group, suggesting a decrease in astrogliosis following neuronal expression of TFEB (Figure 6, C and D), remi-
niscent of what we observed in the A53T–α-syn rat model of PD (Supplemental Figure 1D). Regarding microg-
lia proliferation, no significant differences were observed in microglial Iba1 immunoreactivity in the SN (Figure 
6, E and F) and in the striatum (Figure 6, G and H). These results suggest that targeted TFEB overexpression did 
not change the astrogliosis and microgliosis in the PLP mouse model of MSA.
TFEB expression induces neurotrophic effects. Since TFEB expression was previously associated with neu-
rotrophic effects (26), we wondered whether the neuroprotective effects observed upon oligodendroglial 
expression of  TFEB may be explained by neurotrophic support. As a proxy for branching, we quantified 
TH-positive immunoreactive staining in the SN, reflecting the surface occupied by both the dopaminergic 
Figure 4. Specific oligodendroglial TFEB-targeted overexpression attenuates dopaminergic neurodegeneration in a MSA mouse model. (A) Representa-
tive images of TH staining in the SN of control, CMVie/hSyn-mTFEB–injected, and MBP-mTFEB–injected WT and PLP mice. Scale bar: 500 μm. (B) Number 
of TH- and Nissl-positive neurons counted by stereology in the SN of control, CMVie/hSyn-mTFEB–injected, and MBP-mTFEB–injected WT and PLP 
mice. (C) Representative images of TH staining into the striatum of control, CMVie/hSyn-mTFEB–injected, and MBP-mTFEB–injected WT and PLP mice. 
Scale bar: 500 μm. (D) Dot plot of mean gray-scale values of striatal TH immunoreactivity measured by optical density in the striatum of control, CMVie/
hSyn-mTFEB–injected, and MBP-mTFEB–injected WT and PLP mice. n = 5 per group. White bars, control; blue bars, CMVie/hSyn-mTFEB-HA; green bars, 
MBP-mTFEB-3×Flag. Data represent mean ± SEM. Comparisons were made using 2-way ANOVA and Tukey’s correction for multiple comparisons. *P < 
0.05 compared with WT mice. #P < 0.05 compared with PLP control mice. $P < 0.05 compared with CMVie/hSyn-mTFEB injected PLP mice.
 
8insight.jci.org   https://doi.org/10.1172/jci.insight.129719
R E S E A R C H  A R T I C L E
9insight.jci.org   https://doi.org/10.1172/jci.insight.129719
R E S E A R C H  A R T I C L E
soma and the dopaminergic fibers. Overexpressing TFEB in either neurons or oligodendrocytes led to an 
increase of  nigral TH immunoreactivity, suggesting a possible expansion of  dopaminergic dendrites (Figure 
7, A and B [F(2,29) = 11.95; CMVie/hSyn-mTFEB PLP vs. control PLP, P = 0.0367; MBP-mTFEB PLP vs. 
control PLP, P = 0.0673]). We then confirmed this hypothesis in vitro by differentiating BE(2)-M17 human 
dopaminergic neuroblastoma cells with retinoic acid to induce a neuronal dendrite expansion phenotype 
(36) prior to transfection with the different TFEB-expressing plasmids. We observed that TFEB-transfected 
cells presented an increase in dendritic length measured by Simple Neural Tracer segmentation analysis, 
compared with nontransfected cells (Supplemental Figure 3, A and B; F[2,239] = 41.6, P < 0.0001). These 
results confirmed that overexpression of  TFEB in neuronal cells increases process length and confirms 
neurotrophic effect observed in vivo.
The PI3K/Akt pathway is a relevant signaling pathway for the mediation of  neurotrophic activity 
(37). We thus measured the relative amount of  Akt, as well as its Ser473-phosphorylated/activated form 
(P-Akt), by immunoblotting. The total amount of  Akt protein was increased only when TFEB was over-
expressed in oligodendrocytes (F[2,24] = 8.47, P = 0.012), whereas no difference was observed for its phos-
phorylated form or for the ratio P-Akt/Akt (Supplemental Figure 3, C–F). These results indicated that 
oligodendroglial TFEB–mediated neurotrophic effects took place, at least in part, mediated through the 
regulation of  Akt expression. No effect on the Akt signaling pathway was observed after neuronal-targeted 
TFEB expression, suggesting that the neurotrophic effect observed in this group was independent of  the 
PI3K/Akt pathway activation.
Under basal WT and PLP mutant conditions, the number of  TH- and Nissl-positive cells correlated with 
the surface of  TH-positive immunostaining in the SN, suggesting that the PLP model showed dopaminer-
gic neuronal soma and fiber loss in the SN (Figure 7C; F[1,13] = 5.45, P = 0.06, r² = 0.24). Interestingly, the 
assessment of  the relative contribution of  TFEB-mediated neurotrophic (i.e., TH-positive immunostaining) 
vs. neuroprotective (i.e., number of  TH- and Nissl-positive cells) in the SN revealed differential processes on 
the dopaminergic system according to the targeted cell type. Thus, overexpressing TFEB in oligodendrocytes 
led to both neuroprotective and neurotrophic effects (Figure 7, D and E; PLP control vs. MBP-mTFEB PLP 
mice), while neuronal overexpression of  TFEB led only to neurotrophic effects, which were not sufficient to 
prevent neurodegeneration (Figure 7, D and E; PLP control vs. CMVie/hSyn-mTFEB PLP mice).
Neuronal and oligodendroglial-targeted TFEB induces the autophagic clearance machinery. Since TFEB is 
a master gene in the regulation of  ALP (17–20, 22), we hypothesized that TFEB overexpression could 
lead to a recovery of  the lysosomal machinery through lysosomal biogenesis and autophagy induction, 
which could enhance α-syn clearance. We first analyzed mRNA expression levels from SN patches 
showing that the Tfeb downstream target gene Mcoln1 transcript expression is upregulated in MBP-mT-
FEB PLP–injected mice (Supplemental Figure 4A) associated with an upregulation of  the autopha-
gy-related Tfeb targets such as Map1lc3a, Lamp2b, CtsB, and CtsF genes (Supplemental Figure 4, B–E), 
suggesting a positive regulation of  autophagy/lysosomal genes. Regarding neuronal TFEB overexpres-
sion, we were not able to detect any mRNA levels changes, probably due to a stronger neuronal cell 
death observed in this group (Figure 4).
Because alteration of  lysosomal integrity, and lysosomal membrane permeabilization especial-
ly, have been described in synucleinopathies (38, 39), we next explored whether overexpression of  
Figure 5. Oligodendroglial-targeted, but not neuronal TFEB–targeted, overexpression decreases the burden of aggregated forms of α-syn with no 
effect on phosphorylation at S129 in the nigrostriatal pathway of PLP mice. (A) Representative images of synucleinopathy in the SN of control, 
CMVie/hSyn-mTFEB–injected, and MBP-mTFEB–injected WT and PLP mice. Left panel: α-syn staining using the human-specific α-syn LB509 anti-
body. Middle panel: Serine129-phosphorylated α-syn staining using the EP1536Y antibody. Right panel: α-syn staining using human-specific α-syn 
LB509 antibody after proteinase K treatment. Scale bars: 50 μm; 20 μm (inset, middle panel). The red arrowheads show the S129-positive α-syn 
dots in the SN. (B and C) Number of α-synuclein–positive dots per μm² counted by stereology in the SN of control, CMVie/hSyn-mTFEB–injected, 
and MBP-mTFEB–injected WT and PLP mice without (B) and with (C) proteinase K treatment. (D) Number of Serine129-phosphorylated α-synu-
clein–positive dots per μm² in the SN of control, CMVie/hSyn-mTFEB–injected, and MBP-mTFEB–injected WT and PLP mice. (E) Representative 
images of synucleinopathy in the striatum of control, CMVie/hSyn-mTFEB–injected, and MBP-mTFEB–injected WT and PLP mice. Left panel: α-syn 
staining using the human-specific α-syn LB509 antibody. Right panel: Serine129-phosphorylated α-syn staining using the EP1536Y antibody. Scale 
bar: 100 μm. (F) Quantification of human α-syn LB509–positive immunostaining into the striatum of control, CMVie/hSyn-mTFEB–injected, and 
MBP-mTFEB–injected WT and PLP mice. (G) Quantification of Serine129-phosphorylated α-syn–positive immunostaining in the striatum of control, 
CMVie/hSyn-mTFEB–injected, and MBP-mTFEB–injected WT and PLP mice. n = 5 per group. White bars, control; blue bars, CMVie/hSyn-mTFEB-
HA; green bars, MBP-mTFEB-3×Flag. Data represent mean ± SEM. Comparisons were made using 2-way ANOVA and Tukey’s correction for multiple 
comparisons. *P < 0.05 compared with WT animals. $P < 0.05 compared with PLP control mice.
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TFEB could rescue lysosomal membrane permeabilization in PLP mice. Accordingly, we measured 
Cathepsin-D (CTSD) activity, one of  the most abundant lysosomal proteases, in lysosome-free cyto-
solic fractions. Compared with WT mice, PLP mice displayed significantly increased lysosomal mem-
brane permeabilization, as evidenced by ectopic release of  CTSD into the cytoplasm (Figure 8A). 
Following TFEB overexpression in either neurons or oligodendrocytes, cytosolic CTSD activity was 
fully restored to basal level of  WT mice, suggesting either a protection of  the lysosomal membrane 
integrity or enhancement of  lysosomal biogenesis (Figure 8A). Further supporting a beneficial role 
on the lysosomal machinery, TFEB-injected PLP mice exhibited an increase in the mature form of  
CTSD expression levels in the SN compared with control PLP animals (Figure 8B). Similar results 
were obtained in mouse SN sections by immunostaining of  the autophagosomal marker (LC3) and 
lysosomal-associated membrane protein 2 (LAMP-2) (Figure 8, C and D). We observed that the num-
ber of  LC3- and LAMP-2–positive puncta in transduced dopaminergic neurons (Figure 8C; LC3, con-
trol vs. CMVie/hSyn-mTFEB PLP mice, F[3,36] = 16.75, P < 0.0001; LAMP-2, control vs. CMVie/
hSyn-mTFEB PLP mice, F[3,47] = 8.77, P = 0.001) and in transduced oligodendrocytes (Figure 8D; 
LC3, control vs. MBP-mTFEB PLP mice, F[3,47] = 4.71, P = 0.005; LAMP-2, control vs. MBP-mTFEB 
PLP mice, F[3,36] = 8.49, P = 0.0001) in PLP mice was significantly increased compared with control 
PLP mice. Taken together, these data indicated that TFEB overexpression in neurons or oligodendro-
cytes increased autophagy flux through the formation of  autophagosomes and lysosomal biogenesis, 
enhancing cellular clearance compared with the control group.
Figure 6. Lack of inflammatory reaction changes in the brain of TFEB-injected WT and PLP mice expressed under either the oligodendroglial 
or the neuronal promoter. (A and B) Representative images (A) and quantification (B) of GFAP-positive astrocytic immunostaining in the SN of 
control, CMVie/hSyn-mTFEB–injected, and MBP-mTFEB–injected WT and PLP mice. Scale bar: 200 μm. (C and D) Representative images (C) and 
quantification (D) of GFAP-positive astrocytic immunostaining in the striatum of control, CMVie/hSyn-mTFEB–injected, and MBP-mTFEB–injected 
WT and PLP mice. Scale bar: 50 μm. (E and F) Representative images (E) and quantification (F) of Iba1-positive microglial cells immunostaining in 
the SN of control, CMVie/hSyn-mTFEB–injected, and MBP-mTFEB- injected WT and PLP mice. Scale bar: 200 μm. (G and H) Representative images 
(G) and quantification (H) of Iba1-positive microglial cells immunostaining in the striatum of control, CMVie/hSyn-mTFEB–injected, and MBP-mT-
FEB–injected WT and PLP mice. Scale bar: 50 μm. n = 5 per group. White bars, control; blue bars, CMVie/hSyn-mTFEB-HA; green bars, MBP-mT-
FEB-3×Flag. Data represent mean ± SEM. Comparisons were made using 2-way ANOVA and Tukey’s correction for multiple comparisons. *P < 0.05 
compared with WT animals.
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Figure 7. Both oligodendroglial– and neuronal TFEB–targeted overexpression induce neurotrophic effects in the brains of PLP mice. (A and B) 
Representative images (A) and quantification (B) of TH-positive immunostaining in the ipsilateral SN of control, CMVie/hSyn-mTFEB–injected, and 
MBP-mTFEB–injected WT and PLP mice. Scale bar: 50 μm. (C) Linear regression between TH-positive immunostaining and TH- and Nissl-positive 
cells in the SN of control WT (empty dark dots) and PLP mice (full dark dots). (D) Ratio of TH-positive immunostaining in the ipsilateral SN divided 
by the number of TH- and Nissl-positive neurons into the ipsilateral SN of control, CMVie/hSyn-mTFEB–injected, and MBP-mTFEB- injected WT and 
PLP mice. n = 5 per group. White bars, control; blue bars, CMVie/hSyn-mTFEB-HA; green bars, MBP-mTFEB-3×Flag. (E) Scatter plot of the value of 
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Discussion
Here, we demonstrate that targeting neuronal expression of  TFEB was sufficient to reduce synucle-
inopathy and prevent neurodegeneration in the A53T–α-syn rat model of  PD, while only oligoden-
droglial overexpression of  TFEB leads to neuroprotective effects in the MSA mouse model (Supple-
mental Figure 5). These beneficial effects were associated with a decrease of  the pathological burden 
of  α-syn through recovery of  the ALP machinery. Overall, our study supports the idea that the cellular 
origin of  the synuclein pathology dictates where enhancement of  ALP should occur to allow a neuro-
protective effect.
Numerous studies highlight lysosomal impairment as a key player in the pathogenesis of  synucleinop-
athies such as PD and MSA (40, 41), and several therapeutic strategies based on ALP component over-
expression, such as LAMP-2A (42) or Beclin-1 (43), have been used to increase autophagy machinery in 
experimental models of  neurodegenerative diseases (44). Consistent with this approach, viral-mediated 
neuronal overexpression of  TFEB has been used to mediate neuroprotection in a rat model of  PD-overex-
pressing human WT α-syn (23). We here provide further evidence in another experimental model of  PD. 
Neuronal expression of  TFEB in the human mutated A53T–α-syn rat model of  PD showed nigrostriatal 
dopaminergic neuroprotection and preserved motor function. Those beneficial effects were associated with 
decreased accumulation of  α-syn.
However, no studies were performed so far to elucidate the role of  the ALP in MSA pathogenesis 
and to exploit TFEB as a therapeutic target for this peculiar synucleinopathy. Here, we show that 
nuclear levels of  TFEB are decreased in brains from patients with MSA and address the feasibility 
and therapeutic potential of  restoring TFEB levels in selected cell types in a clinically relevant mouse 
model of  MSA. Because MSA is first regarded as an oligodendrogliopathy, we tested whether TFEB 
overexpression either in neurons or in oligodendrocytes of  the SN of  PLP mouse model may result in 
different biological responses and alleviate MSA-related pathology. We here show that AAV-mediated 
expression of  TFEB was sustainable in our model, and we observed nucleus localization of  exogenous 
TFEB in neuronal cells or oligodendrocytes, which is necessary for its transcriptional role. Contrary 
to our rat model of  PD, neuronal-targeted TFEB in PLP mice did not afford dopaminergic neuropro-
tection, reduction of  synucleinopathy, or a decrease in inflammatory responses. This lack of  efficacy 
of  neuronal expression of  TFEB in a MSA model could be due to the fact that, similar to the disease 
(45), neurons are less affected by the synucleinopathy compared with oligodendrocytes. Surprisingly, 
neuronal expression of  TFEB in both WT and PLP mice showed potent neurotrophic effects, possibly 
linked to modulation of  growth machinery, such as demonstrated in oncology (46), which should be 
further elucidated in future studies.
Importantly, we show that only specific oligodendroglial overexpression of  TFEB in the PLP mice is able 
to partially overcome the deleterious effects associated with this model. According to our central hypothesis, 
overexpression of  TFEB was effective in reversing the dopaminergic neurodegeneration in a higher mag-
nitude at the level of  striatal dopaminergic terminals compared with SN dopaminergic cell bodies through 
alleviation of  the burden of  aggregated α-syn. Notably, we confirmed that oligodendroglial-targeted TFEB 
overexpression also restores ALP function, attenuates lysosomal membrane permeabilization, and induces 
neurotrophic effects. Interestingly, the Akt pathway is involved in the process of  myelination in the CNS (47), 
a role dedicated to the oligodendrocytes (48). This indicates that TFEB induces the Akt prosurvival path-
ways, which may help to reduce oligodendroglial dysfunction and lead to a more efficient myelin production, 
participating in dopaminergic pathway neuroprotection. Of course, future investigations will be necessary 
to determine its exact contribution and whether other prosurvival pathways are involved in the process of  
myelination, such as the TFEB gene target MAPK1/3 (49).
Besides macroautophagy, cellular pathways such as CMA and UPS are involved in the degradation of  
α-syn, including in a MSA context (5, 50). Although enhancing ALP appears clearly efficient for mitigating 
TH surface immunostaining and the number of TH- and Nissl-positive neurons into the ipsilateral SN of control, CMVie/hSyn-mTFEB–injected, and 
MBP-mTFEB–injected WT and PLP mice. Each dot represents 1 animal. Red dot corresponds to the center of mass of each experimental group, and the 
ellipses represent the 95% CI around the center of mass: PLP control (black); CMVie/hSyn-mTFEB PLP (blue); MBP-mTFEB-PLP (green). Dashed lines 
are arbitrarily centered on the center of mass of PLP control group to distinguish between neurotrophic effect (toward upper left quadrant), neuro-
protection (lower right quadrant), and a combination of both (upper right quadrant) in AAV-injected PLP groups; black arrows represent the direction 
of the change. Data represent mean ± SEM. Comparisons were made using 2-way ANOVA and Tukey’s correction for multiple comparisons. *P < 0.05 
compared with control PLP animals. $P < 0.05 compared with control WT animals.
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α-syn accumulation in order to achieve neuroprotection, it could be relevant in future studies to combine 
complementary strategies through gene therapy or pharmacological drugs to enhance CMA and/or the UPS 
systems, in addition to TFEB for further optimizing α-syn clearance in the oligodendrocytes, in an attempt to 
reach even stronger neuroprotective effects.
In summary, the present study validates TFEB as an interesting therapeutic strategy in PD in an addi-
tional PD rat model, which is consistent with previous reports (23, 26, 51). Further supporting this interest, 
we provide the first evidence to our knowledge that targeting TFEB in a cell-specific manner is crucial in 
MSA pathology — i.e., oligodendroglial-targeted TFEB, as opposed to neuronal-targeted TFEB, leads to 
neuroprotective and neurotrophic effects with improvement of  α-syn clearance after activation of  lyso-
somal biogenesis in a transgenic MSA mouse model. Overall, we confirmed the relevance of  targeting 
TFEB expression to enhance ALP as a promising therapeutic approach for all synucleinopathies. TFEB 
has also been validated as an emerging therapeutic target to enhance lysosomal biogenesis and autophagy 
in different disorders — such as Alzheimer’s disease, in which its astrocytic expression decreases misfold-
ed Tau spreading (52) — but also for lysosomal storage disorders, such as Pompe Disease (53), as well as 
for ischemic injury (54), alcoholic liver disease (55, 56), and osteoarthritis (57). Recent reports in which 
Figure 8. TFEB overexpression enhances autophagy-lysosomal pathway function in the brain of PLP mice. (A) Quantification of Cathepsin D (CTSD) 
activity in cytosolic lysosomal-free fraction from ipsilateral SN of control, CMVie/hSyn-mTFEB–injected, and MBP-mTFEB–injected WT and PLP mice. 
(B) CTSD immunoblot levels from ipsilateral SN of control, CMVie/hSyn-mTFEB–injected, and MBP-mTFEB- injected WT and PLP mice. n = 5 per group. 
Lanes were run on the same gel but were noncontiguous. (C) Confocal images (left) and quantification (right) using either TH or HA tag, Lamp-2, and LC3 
antibodies in the ipsilateral SN of mice injected or not with the CMVie/hSyn-mTFEB-HA. The quantification represents the number of LC3- or Lamp-2–
positive puncta into neuronal cells. Scale bar: 100 μm. n = 9–13 per group. (D) Confocal images (left) and quantification (right) using either Olig2 or Flag 
tag, Lamp-2, and LC3 antibodies in the ipsilateral SN of mice injected or not with the MBP-mTFEB-Flag. The quantification represents the number of 
LC3- or Lamp-2–positive puncta into oligodendrocytes. Scale bar: 50 μm. n = 7–30 per group. White bars, control; blue bars, CMVie/hSyn-mTFEB-HA; 
green bars, MBP-mTFEB-3×Flag. Data represent mean ± SEM. Comparisons were made using 1-way ANOVA and Tukey’s correction for multiple compari-
sons. *P < 0.05 compared with control WT animals. #P < 0.05 compared with control PLP animals.
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the FDA-approved drug 2-Hydroxypropyl-β-cyclodextrin (24, 25) or the natural compound pomegranate 
extract (58) are TFEB expression enhancers pave the way for future intervention.
In conclusion, increasing TFEB expression, by gene therapy or through pharmacological activation, 
into the CNS but also into peripheral organs becomes a strongly relevant therapeutic strategy. Further 
investigations to address the extent and localization of  TFEB induction are still fundamental to provide the 
most clinically relevant and safest candidate and therapeutic strategy.
Methods
Plasmid production
Rat study. An AAV plasmid backbone containing the murine Tfeb cDNA fused to 3 Flag epitopes under 
control of  the CMV promoter was provided by TIGEM AAV Vector Core Facility.
Mouse study. AAV containing the murine Tfeb cDNA fused to HA epitope under control of  the CMVie/
hSyn and an AAV containing the murine Tfeb cDNA fused to 3 Flag epitopes under control of  the MBP 
promoter were cloned in our laboratory.
In vitro experiments
Assessment of  Tfeb transgene expression. Human embryonic kidney 293 cells (HEK293T) were obtained 
from ATCC (catalog CRL-11268) and grown in DMEM Low Glucose (MilliporeSigma) plus 10% FBS. 
HEK293T cells were plated into 12-well plates before being transfected with the mTFEB-containing plas-
mids at 1.6μg DNA using Polyethylenimine-mediated (PEI-mediated) transfection for 4 hours. Then, medi-
um was changed, and cells were maintained for 48 hours at 37°C in 5% CO2 before being scraped into 
PBS. After a centrifugation step at 837 g for 5 minutes, the supernatant was removed, and cell pellet was 
lysed in 100 μl of  Laemmli buffer (Tris-HCl 25 mM, pH 6.8, glycerol 7.5%, SDS 1%, DTT 250 mM, and 
Bromophenol blue 0.05% [MilliporeSigma]) for biochemical experiment.
Analysis of  dendritic length. Human neuroblastoma cell line, BE(2)-M17, obtained from ATCC (catalog 
CRL-2267) was cultured in OPTIMEM (Thermo Fisher Scientific) plus 10% FBS supplemented with 1% 
streptomycin/penicillin (MilliporeSigma). M17 were plated on coverslips into a 12-well plates to approxima-
tively 80% confluency before being treated with retinoic acid (MilliporeSigma) at 5 μM for 24 hours (36). Cells 
were then transfected with the mTFEB-containing plasmids at 1.6 μg DNA using PEI-mediated transfection 
for 4 hours. Then, medium was changed, and cells were maintained for 48 hours at 37°C in 5% CO2 before 
being fixed with paraformaldehyde (VWR) at 4% for 30 minutes at 4°C for immunofluorescent staining. The 
fixed cells were washed 3 times with PBS 1× for 5minutes each time. Cells were then permeabilized with 
Triton 0.01% in PBS-NDS 3% for 30 minutes at room temperature before being incubated with the following 
primary antibodies (diluted in 1:1000): β3-tubulin (ab78078, Abcam) plus TFEB (Thermo Fisher Scientific, 
PA1-31552) overnight at 4°C. Cells were then washed 3 times with PBS 1× for 5 minutes each time before 
an incubation with donkey Alexa-conjugated antibodies (1:400, Invitrogen) in PBS. Cells were finally stained 
with DAPI solution (Invitrogen) at 10 μM for 8 minutes before long washes. Coverslips were mounted onto 
slides using mounting solution (Dako), and image acquisitions were made on a wide-field Zeiss Imager M2 
and a CCD Camera Hamamatsu C10600 using Explora Nova MorphoStrider software. The dendritic length 
was measured using a segmentation analysis with the simple neurite tracer plugin of  ImageJ (NIH).
AAV vector production
Recombinant AAV9-CMVie/hSyn-mTFEB-HA-WPRE and AAV9-MBP-mTFEB-3×Flag-WPRE vectors 
were produced by PEI-mediated triple transfection of low-passage HEK-293T/17 cells (ATCC, catalog CRL-
11268). The AAV expression plasmids were cotransfected with the adeno helper pAd Delta F6 plasmid (Penn 
Vector Core, catalog PL-F-PVADF6) and AAV Rep Cap pAAV2/9 plasmid (Penn Vector Core, catalog PL-T-
PV008). AAV vectors were purified as previously described (59). Cells were harvested 72 hours after transfec-
tion, resuspended in lysis buffer (150 mM NaCl, 50 mM Tris-HCl, pH 8.5), and lysed by 3 freeze-thaw cycles 
(37°C/–80°C). The cell lysate was treated with 150 units/ml benzonase (MilliporeSigma) for 1 hour at 37°C, 
and the crude lysate was clarified by centrifugation. Vectors were purified by iodixanol step gradient centrifuga-
tion, and they were concentrated and buffer-exchanged into Lactated Ringer’s solution (Baxter) using vivaspin20 
100 kDa cut-off concentrator (Sartorius Stedim). Titrations were performed at the platform study of the tran-
scriptome (Neurocentre Magendie, INSERM U862). The genome-containing particle (gcp) titer was determined 
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by quantitative PCR (qPCR) using the Light Cycler 480 SYBR green master mix (Roche Diagnostics) with 
primers specific for the AAV2 ITRs (forward, 5′-GGAACCCCTAGTGATGGAGTT-3′; reverse, 5′-CGGCCT-
CAGTGAGC GA-3′) (60) on a Light Cycler 480 instrument. Purity assessment of vector stocks was estimated 
by loading 10 μl of vector stock on 10% SDS acrylamide gels; total proteins were visualized using the Krypton 
Infrared Protein Stain according to the manufacturer’s instructions (Invitrogen). We obtained a titer of 3.06 × 
1012 gcp/ml for the neuronal AAV9-CMVie/huSyn-mTFEB-HA-WPRE and a titer of 1.48 × 1013 gcp/ml for 
the oligodendroglial AAV9-MBP-mTFEB-3×Flag-WPRE.
Rodent experiments and stereotactic inoculations
Rat study. Thirty-two OFA Sprague Dawley rats (male, 2 months old) were injected unilaterally in the SNpc 
with 2 μl of  either the AAV-A53Tα-syn (3.0 × 1012 vg/ml), the AAV-TFEB (3.0 × 1012 vg/ml), or a 1:1 
mixture of  AAV-A53Tα-syn/AAV-TFEB. Under isoflurane anesthesia, rats were placed in a stereotaxic 
frame (Kopf  Instruments) and received 1 unilateral intranigral injections — either first track (–4.9 AP, 2.2 
L, and –7.8 DV) or second track (coordinates from bregma: –5.1 antero-posterior [AP], 2 lateral [L], and 
–7.8 dorso-ventral [DV]) of  either vector, as previously described in refs. 27 and 61.
Mouse study. Homozygous transgenic PLP–α-syn mice (MGI:3,604,008) overexpressing human α-syn 
under the PLP (32) and background-, age-, and sex-matched nontransgenic C57BL/6J mice were used in 
this study (WT mice) — male and female mixed (bred in house). PLP mice were fully backcrossed onto 
C57BL/6J background (n > 15 generations). They were bred and housed in a temperature-controlled room 
under a 12/12 hours dark/light cycle, with free access to food and water.
PLP and WT mice (2 months old) received 2 μl of either AAV9-CMVie/huSyn-mTFEB-HA-WPRE or 
AAV9-MBP-mTFEB-Flag-WPRE virus (concentration: 3.06 × 1012 gcp/ml) by stereotactic delivery to the 
region immediately above the right SN (coordinates from bregma: AP, –2.9, L, –1,3, DV, –4.5) at a flow rate of  
0.4 μl/min, and the pipette was left in place for 5 minutes after injection to avoid leakage. Animals were eutha-
nized after 5 months. Ten mice were used in each group — male and female mixed. Five brains of each group 
were immediately freshly frozen by immersion in a cold isopentane bath at –60°C during 5 minutes and stored at 
–80°C for biochemistry investigation. The 5 others were postfixed for 3 days in 10 ml of 4% paraformaldehyde 
at 4°C, cryoprotected in gradient 20% sucrose in PBS before being frozen by immersion in a cold isopentane 
bath (–60°C) for at least 5 minutes, and stored immediately at –80°C until sectioning for histochemical analysis.
mRNA extraction and qPCR
Nigral samples were homogenized in Tri-reagent (Euromedex), and RNA was isolated using a standard 
chloroform/isopropanol protocol (62). RNA was processed and analyzed following an adaptation of  pub-
lished methods (63). cDNA was synthesized from 2 μg of  total RNA using RevertAid Premium Reverse 
Transcriptase and primed with oligo-dT primers and random primers (Fermentas). qPCR was performed 
using a LightCycler 480 Real-Time PCR System (Roche Diagnostics). qPCR reactions were done in dupli-
cate for each sample, using transcript-specific primers, cDNA (4 ng), and LightCycler 480 SYBR Green 
Master (Roche Diagnotstics) in a final volume of  10 μl. The PCR data were exported and analyzed in 
an informatics tool (Gene Expression Analysis Software Environment) developed at the NeuroCentre 
Magendie. For the determination of  the reference gene, the Genorm method was used (64). Relative expres-
sion analysis was corrected for PCR efficiency and normalized against 2 reference genes. The valosin con-
taining protein (Vcp) and the hypoxanthine guanine phosphoribosyl transferase (Hprt) genes were used as 
reference genes. The relative level of  expression was calculated using the comparative (2–ΔΔCT) method (64).
Primer sequences: Vcp (NM_009503) forward, 5′-TGGCCGTCTAGATCAGCTCAT-3′; Vcp 
(NM_009503) reverse, 5′-TTTCGCAGATTGGCTTTTAGG-3′; Hprt (NM_013556) forward, 5′-AAA-
CAATGCAAACTTTGCTTTCC-3′; Hprt (NM_013556) reverse, 5′-CGAGAGGTCCTTTTC 
ACCAGC-3′; Mcoln1 (NM_053177) forward, 5′-TTCCTGCTGCAGAACGAGTTT-3′; Mcoln1 
(NM_053177) reverse, 5′-CGTTCCCAGAGGCTG ATTTC-3′; Map1lc3a (NM_025735) forward, 
5′-ACACCCATCGCTGACATCTATG-3′; Map1lc3a (NM_025735) reverse, 5′-TGGGAGGCGTAGAC-
CATGTAG-3′; Lamp-2b (NM_010685) forward, 5′-AGATAATTGCTAGGCAGTGCCAA; Lamp-
2b (NM_010685) reverse, 5′-GCTGCATGTAGA GGCCAATTTC-3′; CtsB (NM_007798) forward, 
5′-ATGAGTGCCAGGCCTTTGAATA-3′; CtsB (NM_007798) reverse, 5′-GGCCATCGCCCAAATC-
TAT-3′; CtsF (NM_019861) forward, 5′-GGGC AAGAACCTGGCTACAGTAT-3′; CtsF (NM_019861) 
reverse, 5′-GCCTGCTGAGGACAGATC TAGTTT-3′.
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Biochemical analysis
Total protein extraction and quantification of  mice tissue. Tissue patches (n = 2–3) of mouse SN were extracted on 
ice using 80 μl of  RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1.0% Triton X-100, 0.5% Na-deoxy-
cholate, 0.1% sodium dodecyl sulfate) with a protease inhibitor cocktail tablet (Complete Mini, Roche Diag-
nostics). The lysate was incubated on ice for 20 minutes, centrifuged at 18,220 g for 15 minutes at 4°C. The 
supernatant was collected, and the Bicinchoninic Acid (BCA) Assay (Thermo Fisher Scientific, USA) was used 
to determine the total amount of protein in the lysates and was then stored at –80°C. Based on total protein 
concentrations calculated from the BCA assays, aliquots of tissue lysates corresponding to known amounts of  
total protein per well were prepared for each animal in Laemmli buffer (Tris-HCl 25mM pH = 6.8, Glycerol 
7.5%, SDS 1%, DTT 250mM and Bromophenol blue 0.05%) for the immunoblotting experiment.
Total protein extraction and quantification of  human brain tissue. Human putamen and frontal cortex were 
dissected from fresh frozen postmortem midbrain samples from 7 patients with MSA and 6 healthy con-
trols (mean age at death: 72 ± 2.83 years; frozen postmortem interval: 27.5 ± 6.65 hours; GIE Neuro-CEB 
BB-0033-00011). For human brain samples of  the putamen or the frontal cortex, we separated cytosolic and 
nuclear fractions by methods previously described (28). Proteins were extracted on ice using 1 ml of  buffer A 
(10 mM HEPES, pH 7.9, 10 mM NaCl, 0.1 mM EDTA, and 1 mM dithiothreitol) with a protease inhibitor 
cocktail tablet (Complete Mini, Roche Diagnostics). The homogenate was centrifuged at 837 g for 5 minutes 
at 4°C. The supernatant was collected as cytosolic fractions. For nuclear fractions, the pellet was dissolved in 
buffer B (20 mM HEPES, pH 7.9, 400 mM NaCl, 1 mM EDTA, and 1 mM dithiothreitol) with a protease 
inhibitor cocktail tablet (Complete Mini, Roche Diagnostics) and vortexed on ice for 15 minutes. The homog-
enate was incubated for 30 minutes at 4°C under constant shaking before a centrifugation at 18,220 g for 10 
minutes at 4°C. Supernatant was collected as nuclear fractions. The BCA assay was used to determine the 
total amount of  protein in the nuclear and cytosolic fractions and was then stored at –80°C. Based on total 
protein concentrations calculated from the BCA assays (Thermo Fisher Scientific), aliquots of  tissue fractions 
corresponding to known amounts of  total protein per well were prepared for each individual in Laemmli 
buffer (Tris-HCl 25mM pH = 6.8, Glycerol 7.5%, SDS 1%, DTT 250mM and Bromophenol blue 0.05%) for 
the immunoblotting experiment.
Immunoblotting analysis. Western blots were run from 10 μg of  protein extracts from mouse SN, 20 
μl of  transfected cell lysates, and 20 μg of  protein extracts from brain patients, separated by SDS-PAGE 
and transferred to 0.2 μm nitrocellulose membrane (Bio-Rad). Incubation of  the primary antibodies was 
performed overnight at 4°C with goat anti-mTFEB (1:1,000, Thermo Fisher Scientific, PA1-31552), rabbit 
anti-huTFEB (1:1,000, Cell Signaling Technologies, 4240), goat anti-HA (1:1,000, Genscript, A00168), 
mouse anti-Flag (1:1,000, MilliporeSigma, F3165), mouse anti–cath-D (1:1,000, MilliporeSigma, C0715), 
rabbit anti-Akt (1:1,000, Cell Signaling Technology, 9272), and rabbit anti–Ser473-phosphorylated-Akt 
(1:1,000, Cell Signaling Technology, 9271). Mouse anti-actin (1:2000, MilliporeSigma, A5441) was used 
to control equal loading except for nuclear fraction of  brains patients (LaminA/C, 1:2,000, Genscript, 
A01455). Appropriate secondary antibodies coupled to peroxidase were revealed using a Super Signal West 
Pico Chemiluminescent kit (Immobilon Western, Chemiluminescent HRP substrate, MilliporeSigma). 
Chemiluminescence images were acquired using the ChemiDoc+XRS system measurement (Bio-Rad). 
Signals per lane were quantified using ImageJ, and a ratio of  signal on loading per sample was performed 
and used in statistical analyses. Regarding biochemical experiments on mice tissue, each graph regarding 
immunoblotting experiments on mice represents the quantified protein level normalized by actin protein 
levels. Regarding TFEB protein levels for MSA brains, the calculated ratio nuclear TFEB/cytosolic TFEB 
corresponds to the ratio “nuclear TFEB/Lamin” divided by the ratio “cytosolic TFEB/Actin”. See com-
plete unedited blots in the supplemental material.
CTSD activity assay. CTSD activity was measured in cell lysates using a fluorometric CTSD activity 
assay kit (Abcam, ab65302) in accordance with the manufacturer’s instructions. Fluorescence was mea-
sured on a FLUOstar Optima microplate analyzer (BMG Labtech).
Histopathological analysis
Extent of  lesion. To assess the integrity of  the nigrostriatal pathway, TH IHC was performed on SNpc and 
striatal sections. Briefly, sections from 3 representative levels of  the striatum (anterior, medial, and posteri-
or) and serial sections (1 of  6) corresponding to the whole SNpc were incubated with a rabbit monoclonal 
antibody raised against mouse TH (Abcam, EP1532Y, ab137869, 1:5,000) for 1 night at room temperature 
1 7insight.jci.org   https://doi.org/10.1172/jci.insight.129719
R E S E A R C H  A R T I C L E
and revealed by an anti–rabbit peroxidase EnVisionTM system (DAKO, K400311) followed by DAB visu-
alization. Free-floating SNpc sections were mounted on gelatinized slides, counterstained with 0.1% cresyl 
violet solution, dehydrated, and cover-slipped, while striatal sections were mounted on gelatinized slides and 
cover-slipped. The extent of  the lesion in the striatum was quantified by OD. Sections were scanned in an 
Epson expression 10000XL high-resolution scanner, and images were used in ImageJ open source software to 
compare the gray level in the putamen. TH-positive SNpc cells were counted by stereology, blind with regard 
to the experimental condition using a Leica DM6000B motorized microscope coupled with the Mercator 
software (Explora Nova). The SN was delineated for each slide, and probes for stereological counting were 
applied to the map obtained. Each TH-positive cell with its nucleus included in the probe was counted. The 
optical fractionator method was finally used to estimate the total number of  TH-positive cells in the SNpc of  
each mouse hemisphere. In addition, we measured the Nissl cell count and the surface of  TH occupied in SN 
to fully characterize the pattern of  dopaminergic cell loss in the SN. The surface is an additional quantification 
method that we use in tissue sections. For these analyses, a specific staining process was used to keep all tis-
sues together in the same solution during the staining process, counterstained with 0.1% cresyl violet solution. 
Then, high-resolution whole color slide images were first acquired with the 3D Histech Panoramic Scanner at 
the 20× magnification, with 5 layers in extended mode. Each image was opened in the off-line MERCATOR 
PRO 7.12.3 software (Explora Nova), and the mapping of  all regions of  interest was made. Brightness and 
contrast rules were applied to the RGB pictures to optimize details without any saturation of  the image. The 
color thresholding tool was then used to select the threshold corresponding to the brown color revealed by the 
DAB staining. The threshold has been established on the basis of  the staining intensity to detect the maximum 
of DAB staining. The file of  the threshold parameters was saved and applied to all measurements for each 
animal/staining. Before performing the quantification, the threshold was randomly applied to some images 
of  different treatment groups to verify the accuracy of  settings. In each region, the software extracted the sur-
face corresponding to the threshold defined. The surface parameter was finally expressed as a ratio of  the total 
surface of  each area of  interest. Conversely, the stereology approach allowed us to obtain an unbiased number 
of  cells, while the threshold surface analysis allowed us to quantify any antibody-based staining in the region 
of  interest. Both, therefore, are needed.
α-Syn pathology. Synucleinopathy has been assessed with a mouse monoclonal antibody raised against 
human α-syn (Novex, Invitrogen, LB509, 180215, 1:1,000) using the M.O.M. Vector kit protocol and against 
phosphorylated α-syn (Abcam, EP1536Y, ab51253, 1:5,000) immunostaining, as we previously reported 
(27, 65). Briefly, selected sections of  1 rostro-caudal level of  SN and striatum were specifically identified 
and incubated in the same well to allow direct comparison of  immunostaining intensity. For pretreatment 
with PK, sections were incubated first with PK at 10 μg/ml in PBS before long sequential washes in distilled 
water and then in PBS. Sections were incubated overnight at room temperature with the aforementioned 
antibodies. The following day, revelation was performed with anti-species peroxidase EnVision system 
(DAKO) followed by DAB incubation. Sections were then mounted on gelatinized slides, dehydrated, count-
er-stained if  necessary, and cover-slipped until further analysis. LB509-positive dots in SN were counted by 
stereology, blind with regard to the experimental condition using a Leica DM6000B motorized microscope 
coupled with the Mercator software (Explora Nova). The SN was delineated for each slide, and probes for 
stereological counting were applied to the map obtained (size of  probes was 60 × 80 μm) and transform 
as object after counting. The optical fractionator method was finally used to estimate the total number of  
LB509-positive dots per μm² in the SN of  each mouse. LB509 immunostaining–positive surface in the stria-
tum and phosphorylated α-syn immunostaining–positive surface quantification in the SN and the striatum 
were performed as previously (27).
Inflammation. Inflammatory processes in the SN and the striatum were measured through 
GFAP/S-100 (DAKO, Z0334/Abnova, PAP11341) and Iba1 (Abcam, ab5076) IHC. Striatal sections 
of  all animals were incubated together overnight with a mix of  rabbit antibodies raised against GFAP 
and S-100 for the astroglial staining (respective dilutions 1:2,000 and 1:1,000) and with a rabbit anti-
Iba1 antibody for the microglial staining (dilution 1:1,000). These signals were revealed with anti-spe-
cies peroxidase EnVision system (DAKO) followed by DAB incubation. Sections were mounted on 
slides, dehydrated, and cover-slipped. Sections were scanned in a high-resolution scanner (PanScan, 
3D Histech) at ×20 magnification, and the quantification of  GFAP-positive astrocytic reaction or 
Iba1-positive microglial reaction was estimated by an immunostaining-positive surface quantification 
at regional levels with the Mercator software (Explora Nova).
1 8insight.jci.org   https://doi.org/10.1172/jci.insight.129719
R E S E A R C H  A R T I C L E
Immunofluorescent images
For 2′,3′-cyclic nucleotide-3′-phosphodiesterase (CNPase) and Flag fluorescent costaining. For CNPase staining, tyra-
mide signal amplification (TSA) protocol kit was used. Briefly, sections were permeabilized for 30 minutes 
in TSA blocking buffer containing 0.1% Tween20 (MilliporeSigma) and incubated overnight at room tem-
perature with mouse anti-CNPase (Abcam, ab6319, 1:1,000) primary antibody diluted in a 1% goat serum/
PBS buffer. Sections were then washed with PBS 3 times for 10 minutes and then incubated for 10 minutes 
in PBS/H2O2 3%. After washing, sections were incubated for 2 hours with a goat biotinylated anti-mouse 
(Vector Laboratories, BA-9200) (1:200) at room temperature. Sections were then washed 3 times in PBS 
before being blocked with a streptavidin HRP diluted in TSA blocking solution (1:100) for 30 minutes. 
After an amplification step with Biotinyl tyramide diluted in amplification diluent followed by 3 washes 
in PBS, sections were incubated with goat anti–mouse biotinylated IgG conjugated to AlexaFluor probe 
488 (Invitrogen, 1:1000) for 30minutes. Sections were then washed and incubated with rabbit anti-Flag 
(MilliporeSigma, F7425, 1:500) overnight before 3 steps of  wash. Then, sections were incubated with goat 
anti–rabbit IgG conjugated to AlexaFluor 568 (Invitrogen, 1:1,000) for 1.5 hours in PBS. Tissues were 
then washed with PBS and mounted in DAPI-containing mounting media (Vectashield). Illustrative images 
were acquired using a confocal microscope Leica SP8 at the BioImaging Center in Bordeaux.
HA and TH fluorescent costaining. Sections were permeabilized for 1 hour in a 4% donkey serum/PBS block-
ing buffer containing 0,3% Triton X-100 (MilliporeSigma) and incubated overnight at 4°C with the following 
primary antibodies diluted in a 1% Donkey serum/PBS buffer: rabbit anti-TH (Abcam, EP1532Y, ab137869, 
1:2,000) and goat anti-HA (Genscript, A00168, 1:500). Following incubation with primary antibodies, tissues 
were washed with PBS 3 times for 10 minutes and incubated for 1.5 hours at room temperature with a com-
bination of corresponding donkey anti-species IgG conjugated to AlexaFluor probe (Invitrogen, 1:400). Tis-
sues were then washed with PBS and mounted in DAPI-containing mounting media (Vectashield). Illustrative 
images were acquired using a confocal microscope Leica SP8 at the BioImaging Center in Bordeaux.
Lamp2 and LC3 staining. Sections were permeabilized for 1 hour in a 4% donkey serum/PBS blocking 
buffer containing 0.3% Triton X-100 (MilliporeSigma) and incubated overnight at 4°C with the following 
primary antibodies diluted in a 1% donkey serum/PBS buffer: mouse anti-TH (Merck, MAB318, 1:2,000), 
goat anti-HA (Genscript, A00168, 1:500), mouse anti-Olig2 (Merck, MABN50, 1:500), mouse anti-Flag 
(1:1,000, MilliporeSigma, F3165, 1:500), rat anti–Lamp-2 (Abcam, Abl93, ab25339, 1:1,000), and rabbit 
anti-LC3 (Novus Biological, NB2220, 1:1,000). Following incubation with primary antibodies, tissues were 
washed with PBS 3 times for 10 minutes and incubated for 1.5 hours at room temperature with a combina-
tion of  corresponding donkey anti-species IgG conjugated to AlexaFluor probe (Invitrogen, 1:400). Tissues 
were then washed with PBS and mounted in DAPI-containing mounting media (Vectashield). Illustrative 
images were acquired using a confocal microscope Leica SP8 at the BioImaging Center in Bordeaux.
Statistics
Statistical analyses were performed with GraphPad Prism 6.0 (GraphPad Software Inc.). For rat experi-
ments, comparisons among means were performed by using 1-way ANOVA followed, if  appropriate, by a 
pairwise comparison between means by Tukey post hoc analysis. For in vivo mice experiments, comparisons 
among means were performed by using 2-way ANOVA followed, if  appropriate, by a pairwise compari-
son between means by Tukey post hoc analysis. For in vitro experiments, comparisons among means were 
performed by using nonparametric 2-tailed t test or 1-way ANOVA followed, if  appropriate, by a pairwise 
comparison between means by Tukey post hoc analysis. All values are expressed as the mean ± SEM. Each 
dot in the scatter plot represents 1 individual. In all analyses, statistical significance was set at P < 0.05. For 
Figure 7C, code was written using the Python scientific stack and plotted using Matplotlib (66–68).
Study approval
Animals. Experiments were performed in accordance with the European Union directive of  September 22, 
2010 (2010/63/EU), on the protection of  animals used for scientific purposes. The Institutional Animal 
Care and Ethical Committee of  Bordeaux University (CE50, France) approved experiments accepted by 
the ministry under reference APAFIS 9921-2017031014326763 v5.
Human tissues. Samples were obtained from brains collected in a Brain Donation Program of  the Brain 
Bank GIE NeuroCEB run by a consortium of  Patient Associations: association for research on multiple 
sclerosis (ARSEP), cerebellar ataxias (CSC), France Alzheimer, and France Parkinson. The consents were 
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signed by the patients themselves or their next of  kin in their name, in accordance with the French Bioeth-
ical Laws. The Brain Bank GIE NeuroCEB (Bioresource Research Impact Factor number BB-0033-00011) 
has been declared at the Ministry of  Higher Education and Research and has received approval to distrib-
ute samples (agreement AC-2013-1887).
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